Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(+)-Abscisic acid (HB4674)
Description:Phytohormone and endogenous lanthionine synthetase C-like 2 (LANCL2) ligand
Purity:>99%
Kainic acid (HB0355)
Description:Prototypic, selective kainate receptor agonist. Potent excitant and neurotoxin.
Purity:>98%
MOG (35-55) (HB5273)
Description:Myelin oligodendrocyte glycoprotein fragment. Induces experimental multiple sclerosis-like disease.
Purity:>95%